Home > Boards > US OTC > Biotechs > Xenomics Inc. (XNOM)

XNOM the stock to own:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
cannonball2010 Member Profile
Followed By 1
Posts 67
Boards Moderated 0
Alias Born 01/03/05
160x600 placeholder
cannonball2010   Saturday, 08/06/05 10:38:04 PM
Re: None
Post # of 9 
XNOM the stock to own:

Xenomics Establishes Department of Licensing and Intellectual Property, Hires Veteran Patent Agent David Ladner to Head Unit

Thursday March 24, 4:01 pm ET

Former Bayer and American Cyanamid Executive Will Direct Company's Intellectual Property and Licensing Business

NEW YORK--(BUSINESS WIRE)--March 24, 2005--Xenomics, Inc. (OTCBB:XNOM - News), a developer of next-generation medical DNA technologies, has announced the formation of a Department of Licensing and Patents to manage the growth and licensing business of the Company's expanding intellectual property portfolio. Dr. David Ladner, a patent agent and research scientist with extensive background in the pharmaceutical and chemical industries, has been hired to lead the new unit in the position of Director of Licensing and Intellectual Property.

"The continued expansion of our intellectual property portfolio and the potential for licensing revenues is central to Xenomics' strategic plans for growth and increased shareholder value," said Dr. Randy White, CEO of Xenomics. "As we move from research to commercial product development our intellectual property portfolio has already started to expand in both the U.S. and Europe. Dr. Ladner's appointment as Director of Licensing and Intellectual Property is a key addition to help us manage our growth in this crucial area."

Xenomics is developing and commercializing proprietary gateway DNA testing technology that has the potential to significantly expand the field of molecular diagnostics, currently a $1.5 billion segment of the health care and biotechnology industry. The Company is using its patented Transrenal DNA-based technology platform to develop a number of medical tests for infectious diseases including AIDS and tuberculosis, and for prenatal genetic testing, including gender determination, Rh incompatibility and Down syndrome. Xenomics' breakthrough technology enables detection of DNA using safe, simple and non-invasive urine collection, which offers a number of significant advantages over current techniques that require blood or tissue sampling.

Dr. Ladner, a longtime senior research scientist with extensive experience as a patent agent and specialist in the chemical and pharmaceutical industries, holds a Ph.D. in Organic Chemistry and is currently pursuing an MBA. He was a manager of Intellectual Property at Bayer Pharmaceutical Division for the last five years, where he handled patent filing and prosecution for Chemical Research. He also served as Patent Liaison as well as Research Manager at American Cyanamid Co., for over 20 years, overseeing key aspects of patents and intellectual property. Dr. Ladner holds 22 patents himself, and has published widely in professional journals.

"We are lucky to have someone with David's experience to guide our patent expansion and licensing business," said Dr. White. "His scientific background and technical knowledge of the patent and licensing area is a perfect combination for interaction with our scientific staff."

"I'm excited to bring my experience in patents and licensing to a company with such great potential as Xenomics," said Dr. Ladner. "I believe the company is poised to make extensive and important scientific discoveries, and I look forward to being a part of the team."

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using trans-renal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.

Xenomics, Inc.
Randy White, 212-297-0808
Trilogy Capital Partners, Inc. (Investor Relations)
Paul Karon, 800-342-1467

Source: Xenomics, Inc

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences